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Abstract
Background—Randomized, controlled trials demonstrate the efficacy of arginine-enriched 
nutritional supplements (immunonutrition) in reducing complications after surgery. The 
effectiveness of preoperative immunonutrition has not been evaluated in a community setting.
Objective—Determine whether immunonutrition prior to elective colorectal surgery improves 
outcomes in the community at large.
Design—Prospective cohort study with a propensity score matched comparative effectiveness 
evaluation.
Settings—Washington State hospitals in the Surgical Care Outcomes Assessment Program from 
2012–2015.
Patients—Adults undergoing elective colorectal surgery.
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Interventions—Surgeons used a preoperative checklist that recommended patients take oral 
immunonutrition (237mL, three times daily) for five days prior to elective colorectal resection.
Main outcome measures—Serious adverse events (infection, anastomotic leak, reoperation, 
and death) and prolonged length of stay.
Results—3,375 patients (mean age 59.9±15.2 years, 56% female) underwent elective colorectal 
surgery. Patients receiving immunonutrition more commonly were in a higher American Society 
of Anesthesiologists class (III–V, 44% vs. 38%, p=0.01) or required an ostomy (18% vs. 14%, 
p=0.02). The rate of serious adverse events was 6.8% vs 8.3% (p=0.25) and prolonged length of 
stay was 13.8% vs 17.3% (p=0.04) in those who did and did not receive immunonutrition, 
respectively. After propensity score matching, covariates were similar among 960 patients. 
Although differences in serious adverse events were non-significant (RR 0.76, 95% CI:0.49–1.16), 
prolonged length of stay (RR=0.77, 95% CI:0.58–1.01 p=0.05) was lower in those receiving 
immunonutrition.
Limitations—Patient compliance with the intervention was not measured. Residual confounding 
including surgeon-level heterogeneity may influence estimates of the effect of immunonutrition.
Conclusions—Reductions in prolonged length of stay, likely related to fewer complications, 
support the use of immunonutrition in quality improvement initiatives related to elective colorectal 
surgery. This population-based study supports previous trials of immunonutrition, but shows a 
lower magnitude of benefit, perhaps related to compliance or a lower rate of adverse events, 
highlighting the value of community-based assessments of comparative effectiveness.
Keywords
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INTRODUCTION
Despite advances in technique and perioperative care, approximately 20–25% of people 
undergoing elective colon resections develop infectious, anastomotic, or wound 
complications.1–3 Infections comprise the single most common cause of complications and 
are estimated to cost $10 billion annually.4 Surgical complications are related to a patient’s 
nutritional status and this effect may be exerted through several mechanisms. Preoperative 
malnutrition, due to poor oral intake, significantly increases the risk of adverse events after 
surgery and leads to increased length of stay.5 Another mechanism by which nutrition plays 
a role in surgical complications involves arginine, an amino acid which is found in nitrate-
rich foods. There is a known depletion of arginine related to the stress of surgery.6,7 This 
acute arginine “deficiency” occurs due to inflammation and tissue injury and causes both 
altered nitric oxide synthesis and T-cell dysfunction. Both of these predispose patients to 
infection and impaired wound healing.8–10 This acute deficiency of arginine is potentially 
modifiable by preoperative supplementation of arginine. A number of commercial products 
contain arginine. This group of products is known as immunonutrition and is marketed for 
the reduction of infection and in surgical and critical care populations.
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Immunonutrition reduced the incidence of infections, surgical complications or length of 
stay in 39 studies randomizing more than 2600 patients,11,12 and seven RCTs have 
compared the use of preoperative immunonutrition with controls undergoing gastrointestinal 
surgery. A meta-analysis of these trials showed a near halving of infectious complications 
(RR=0.51, 95% CI 0.35–0.73) in patients receiving immune enhancing nutrition 
preoperatively.12 The mean length of stay was also shorter among patients who received 
immunonutrition in these studies (13.6 versus 15.3 days, p<0.01).
Despite these encouraging findings, no study has examined the comparative effectiveness of 
immunonutrition use across varied clinical practices outside of a clinical trial. Ideally, an 
effectiveness assessment evaluates outcomes in a non-research center setting, including a 
variety of patients, disease states and clinicians from both academic and community 
hospitals, and without the restrictive criteria of a trial. Evidence of an intervention’s 
effectiveness may strengthen the results from efficacy studies and addresses the question of 
generalizability to other populations and communities. The purpose of this study was to 
examine the effectiveness of immunonutrition after colorectal surgery as part of a state-wide 
public health intervention conducted across surgeons’ practices at rural community 
hospitals, urban secondary and tertiary hospitals, and a single academic medical center in 
Washington State (WA).
MATERIALS AND METHODS
The Surgical Care and Outcomes Assessment Program (SCOAP) is a quality-improvement 
collaborative of over 50 hospitals in WA State that began in 2006. SCOAP hospitals include 
six critical access hospitals, numerous rural and urban secondary and tertiary medical 
centers, and a single quarternary referral center. Strong for Surgery (S4S) is a statewide 
public health campaign developed by investigators at the University of Washington’s 
Surgical Outcomes Research Center (funded in part through the Agency for Healthcare 
Research and Quality, Grant Number R01HS020025) that focuses on implementation of 
evidence based practices to optimize patients’ health before surgery. Initiated in 2012, S4S 
engages with surgeons by employing preoperative checklists that guide providers in 
promoting smoking cessation, assuring preoperative medication reconciliation, and 
nutritional optimization before surgery. For patients undergoing elective gastrointestinal 
surgery, S4S promotes the routine use of immunonutrition prior to surgery. Surgeons 
participate voluntarily in S4S. Beginning in 2011, in order to measure the effectiveness of 
preoperative immunonutrition, SCOAP began prospectively recording the use of 
immunonutrition at all of its member hospitals, many of which include surgeons who 
participate in S4S.
We conducted a prospective cohort study of all adult patients undergoing colorectal surgery 
in the SCOAP collaborative during the time period of interest. Patients were included in the 
study if they underwent surgery at one of the SCOAP hospitals between January 1, 2012, 
and June 30, 2015. In order to control for hospital-level factors we only included patients 
from hospitals that administered immunonutrition to at least 10 patients during the study 
period (n=7 hospitals). Patients were excluded from this study if they underwent an 
emergency surgery or if they had an urgent condition for which they would not qualify for 
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preoperative immunonutrition (bowel obstruction, colon ischemia, perforation, 
gastrointestinal bleeding, or volvulus). Patients younger than 18 were excluded. At all 
hospitals, trained abstractors examined charts to determine whether surgeons instructed the 
patient to take immunonutrition prior to surgery. Patients receiving immunonutrition were 
instructed to take the oral supplement (Impact, 237mL; Nestle USA Inc., Glendale, CA) by 
mouth three times daily for the five days prior to surgery. This regimen matched the 
prescribed course of immunonutrition in most clinical trials.
Abstractors reviewed the medical record for demographic, laboratory, operative, and other 
clinical details, including outcomes, during the 30-day period following surgery. The 
primary outcome was any serious adverse events (SAE) including infection [surgical site 
infection (SSI), abscess, urinary tract infection, and pneumonia], reoperation, anastomotic 
leak, and death. The secondary outcome was prolonged length of stay (PLOS) as defined by 
any length of stay greater than 1.5-times the median length of stay in the final cohort. 
SCOAP variable definitions are available online (http://www.scoap.org).
Patient characteristics are summarized by frequencies (categorical variables) and means with 
standard deviation (continuous variables). To evaluate for differences between patients who 
did and did not receive immunonutrition, we performed a univariate analysis with chi-
squared tests or Fisher’s exact tests (categorical variables) and 2-tailed unpaired Student’s t-
tests (continuous variables).
Because of significant differences between patients who were recommended to receive 
immunonutrition and those patients who did not, we performed a one-to-one propensity 
score matching of the two groups. Based upon a logistic regression model including all 
demographic and clinically relevant covariates including age, body mass index (BMI), 
American Society of Anesthesiology (ASA) class, indication, operation type, use of 
colostomy, and insurance type, we calculated a propensity score as the probability of 
receiving immunonutrition for each patient. There was a significant increase in use of 
immunonutrition over time from the beginning to the end of the study, so the regression 
model for calculating propensity scores also controlled for year in the study. Because of 
differences in surgeon and hospital practices, and the influence of other quality 
improvements such as Enhanced Recovery after Surgery (ERAS), there was concern that 
variation across hospitals may lead to bias and confounding in both the receipt of 
immunonutrition and outcomes. In order to account for these differences, patients receiving 
immunonutrition were only matched one-to-one with non-treated patients from their own 
hospital using a nearest-neighbor and no replacement method. After matching within each 
hospital, effects of immunonutrition on primary and secondary outcomes were assessed 
using an unadjusted generalized linear model with a binomial distribution and a log link.
All statistical analyses were performed using commercially available software (Stata, 
version 14; StataCorp, College Station, TX; R-software, version 3.1.3). All statistical tests 
were considered significant if p ≤ 0.05. This study was exempted from institutional review 
board (IRB) review by agreement of the Washington State IRB and UW Human Subjects 
committee. All data used in this analysis were de-identified.
Thornblade et al. Page 4














A total of 3,375 patients (mean age 59.9±15.2 years, 56% female) underwent elective colon 
(79%) or rectal (21%) surgery at seven hospitals. A total of 642 patients (18.7%) were 
instructed by their surgeon to take immunonutrition prior to surgery. With each passing year 
in the study, patients were more likely to receive immunonutrition, 1.4% in 2012 versus 
34.1% in 2015. Patients who received immunonutrition were less often female (52% vs. 
57%, p=0.02), included more patients in the higher ASA classes (III–V, 44% vs. 38%, 
p=0.01), more commonly had diagnoses of cancer (60% vs. 50%, p<0.01) or inflammatory 
bowel disease (14% vs. 8%, p<0.01), and more commonly required an ostomy (18% vs. 
14%, p=0.02) (Table 1). PLOS (1.5x the median LOS) in the final matched cohort was any 
stay greater than 8 days.
The unadjusted rate of SAE was 6.8% in the group receiving immunonutrition and 8.3% 
among those who did not receive treatment (p=0.25). PLOS was 13.8% in the 
immunonutrition group and 17.3% in the untreated group (p=0.04). PLOS was more 
common among patients with than without SAE (73.4% vs. 13.1%, p<0.001). Figure 1 
shows the distribution of propensity scores between patients recommended to receive 
immunonutrition and patients who did not receive immunonutrition. 480 patients receving 
immunonutrition were matched to 480 non-treated patients at their own hospitals. After 
matching, there were no significant differences in demographic or operative characteristics 
between patients in the treated and non-treated groups (Table 2).
After matching, the rate of SAE was 7.1% in the group receiving immunonutrition and 9.4% 
in those who did not (RR=0.76, 95% CI: 0.49–1.16, p=0.19). The relative risk of prolonged 
length of stay was 23% lower among patients receiving immunonutrition (15.6%) compared 
with the untreated group (20.4%) (RR=0.77, 95% CI: 0.58–1.01, p=0.05).
DISCUSSION
This study examined the effectiveness of preoperative immunonutrition among patients 
undergoing elective colorectal surgery. There was a 23% reduction in PLOS associated with 
immunonutrition use. Although non-significant, we found a 24% reduction in SAE 
(infections, anastomotic leaks, reoperation, and death) among patients recommended to take 
immunonutrition that appeared to be related to the reduction in PLOS. Importantly, our 
estimate of reduced adverse events is similar in magnitude to that identified in a meta-
analysis of randomized trials (33%).12
For decades, researchers have explored the role of nutrients, including arginine, in the 
treatment of patients with inflammation after physical injury, including surgery, with the 
goal of identifying a modifiable target to improve outcomes. Arginine has been proposed as 
one of those targets, in part because of the several implicated roles it plays in mitigating the 
harmful effects of inflammation. Arginine is a known substrate for immune cells, and 
arginine deficiency appears to lead to T-cell dysfunction in animal models.6,8,10 Arginine is 
also a precursor for polyamines and hydroxyproline, compounds involved in wound healing. 
In the early 2000’s arginine supplementation was found to reduce infectious complications 
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in patients undergoing elective surgery,11 although the exact mechanism for this effect is still 
under debate. Compounding the challenge of evaluating arginine is that many of the 
commercial preparations that include arginine also include Omega-3 fatty acids, and these 
too may have an effect on surgical outcomes.13
Numerous RCTs have examined the efficacy of different immune enhancing diets in 
gastrointestinal surgery.14,15 Drover et al.4 reviewed 33 studies randomizing patients to 
perioperative use of immunonutrition around the time of elective surgery.16–48 They reported 
a 39% reduction in infectious complications as well as significantly lower lengths of stay. 
Notably, 18 of the 21 trials on gastrointestinal (GI) surgery were in patients undergoing 
upper GI surgery. Among trials of lower GI surgery (n=2) there were no differences in 
length of stay, however complication rates were lower in treated patients. Seven trials 
included use of immunonutrition exclusively in the preoperative period, and aggregated 
results showed a 43% reduction in infectious complications but no difference in length of 
stay.16,18,30,36,37,47,48 A recent Cochrane review includes a meta-analysis of six trials of 
preoperative immunonutrition and reports a 33% reduction in total complications among 
patients receiving immunonutrition in GI surgery.12,16,18,30,36,37,48
Recent meta-analyses have brought into question the efficacy of immunonutrition, in part 
because of differences in both timing of administration and comparison groups.49,50 Hegazi 
et al.49 reviewed trials of preoperative immunonutrition and found a reduction in infectious 
complications (OR=0.49, p<0.01) when compared to control patients receiving no 
supplementation. But when comparing preoperative immunonutrition to controls that did 
receive oral supplementation, the difference in infectious complications was not significant 
(OR=0.71, p=0.44).16,18,30,36,37,47,51–58 Failure in this analysis to detect a difference in 
outcomes may have occurred because of a subdividing of the cohort by control type, 
resulting in smaller sample sizes.59
There have been no prior studies that examine outcomes of immunonutrition outside of a 
clinical trial, where compliance may be a challenge, and where there is more heterogeneity 
in clinical practice and patient characteristics. We found that the recommendation to take 
immunonutrition before surgery was associated with a reduced rate of PLOS, and that PLOS 
was related to SAE. The relative risk reduction associated with immunonutrition was not 
statistically significant, but the direction of effect on SAE was similar (a lowering of 24%) to 
many prior RCTs. One explanation that may account for this was the relatively low rate of 
observed infectious complications in our study (7.1% vs. 9.4% in patients not receiving 
immunonutrition) compared to previously reported studies. The review by Drover et al. 
reported a 41% reduction in infectious complications among 28 trials reporting infections, 
but observed this effect with a much higher rate of adverse events (16.5% vs. 27.7%, 
p<0.0001).4 Burden et al. also reported significant reductions in infectious complications 
(14.2% vs. 27%, p<0.001) but with a similarly high level of events.12 Based upon a sample 
size estimation, a study designed to detect the risk reduction identified in our study (from 
9% to 7%) would require enrollment of 2,987 patients per arm. This suggests that our study 
may be underpowered to detect significant reductions in serious complication rates. This 
difference in adverse event rates may be due to the predominance of high-risk and upper GI 
surgery in trials (esophagectomy, gastrectomy, and pancreaticoduodenectomy) compared 
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with the relatively lower-risk colorectal resections included in this study. Lower 
complication rates observed in this study also may be due to concurrent implementation of 
ERAS protocols over the same period. We did observe a difference in rates of 
immunonutrition use between earlier and later years in this study, and the regression model 
used to calculate propensity scores adjusted for year to account for this observation.
There are several limitations to this study. In particular, confounding by indication may have 
occurred, meaning that patients who received the intervention are different in both measured 
and unmeasured factors from those who did not receive it. Propensity score matching allows 
for a comparison of patient groups that are more balanced in measured factors, allowing 
them to look more like populations from a randomized trial which are balanced through the 
randomization process. Using this approach, patient, clinical and surgical factors were not 
significantly different between matched groups. The SCOAP database does not provide 
surgeon-specific data such as number of years in practice or fellowship training. However, 
by exclusively matching patients recommended to receive immunonutrition to non-treated 
patients from the same hospitals, we hoped to control for major differences in outcome that 
may be due to surgeon factors. Patients who received immunonutrition either paid for it 
themselves or were provided the supplement from the clinic or hospital free of charge. There 
is a possibility that patients with limited financial resources were unable to access 
immunonutrition. However, the rates of Medicaid insurance among those who did and did 
not receive immunonutrition was similar (15.7% vs 14.1%). It is unclear whether patients 
who were advised to take immunonutrition actually complied with the recommendation, and 
if so, took all of the supplements. Rather, SCOAP abstractors identify whether the patients 
were instructed by their surgeon to take the supplement by reviewing the medical record. 
This may represent a conservative bias (e.g., some patients who appear to have received the 
supplement did not in fact use it). This bias might be expected to minimize differences in 
outcomes between groups, and if accounted for, might even accentuate the observed 
differences. It is also possible that, during the early phases of this study, the low rate of 
immunonutrition use was because the recommendation for receipt of the supplement was not 
documented consistently. This is also a bias which might be expected to minimize the 
observed difference between treatment and non-treatment. Lastly, most patients who 
received immunonutrition were also part of the broader S4S initiative focused on improved 
glucose control, smoking cessation, and medicine reconciliation. While not controlling for 
these elements directly, after matching we found no significant differences in perioperative 
hyperglycemia (10.8% vs 9.4%), cigarette smoking (27.9% vs. 27.1%) or beta blocker 
continuation (95.9% vs. 93.1%) between the groups who did and did not receive 
immunonutrition.
In conclusion, the use of preoperative immunonutrition as part of the S4S public health 
campaign helped to improve surgical outcome and was associated with fewer patients 
requiring a PLOS (≥8 days). This study supports the adoption of immune enhancing 
nutrition before elective surgery as a way to reduce prolonged length hospitalizations and 
improve the quality of surgical care.
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Distribution of propensity scores between patients recommended to receive immunonutrition 
and patients who did not receive immunonutrition. Higher scores represent a higher 
propensity for receipt of immunonutrition.
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Table 1
Patient characteristics and outcomes for entire study cohort.






Age, mean (SD), year 60.2 (15.1) 58.9 (15.4) 0.06
Female 1554 (57%) 326 (52%) 0.02
BMI 27.9 (6.4) 28.0 (6.9) 0.9
Race 0.59
 Non-white 305 (11%) 75 (12%)
 White 2312 (84%) 523 (83%)
 Unknown 126 (5%) 34 (5%)
Year <0.01
 2012 997 (36%) 15 (2%)
 2013 761 (28%) 207 (33%)
 2014 685 (25%) 255 (40%)
 2015 300 (11%) 155 (25%)
ASA Class 0.01
 I–II 1710 (62%) 357 (56%)
 III–V 1033 (38%) 275 (44%)
Prior pelvic or colon surgery1 1264 (46%) 283 (45%) 0.58
Indication <0.01
 Cancer 1383 (50%) 379 (60%)
 Diverticulitis 496 (18%) 101 (16%)
 Inflammatory bowel disease 226 (8%) 87 (14%)
 Other indication2 638 (23%) 65 (10%)
Surgical type 0.19
 Colon resection 2189 (80%) 489 (77%)
 Rectal resection 554 (20%) 143 (23%)
Ostomy Created 396 (14%) 116 (18%) 0.02
Insurance status 0.25
 Private insurance 1395 (51%) 338 (53%)
 Non-private insurance 1348 (49%) 294 (47%)
Serious Adverse events 227 (8%) 43 (7%) 0.25
Length of Stay, mean (SD), day 5.7 (4.9) 5.5 (4.8) 0.28
Prolonged Length of Stay (≥8 days) 475 (17%) 87 (14%) 0.04
1
Prior pelvic or colon surgery includes hysterectomy, cholecystectomy, appendectomy and small bowel and colon resections in the pelvic area.
2
Other indications include arterial malformation, iatrogenic injury, rectal prolapse, stricture, or gynecologic malignancy
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Table 2
Patient characteristics and outcomes after propensity score matching.






Age, mean (SD), year 57.9 (15.7) 58.4 (15.5) 0.66
Female 248 (52%) 239 (50%) 0.61
BMI, mean (SD) 28.1 (6.5) 27.7 (6.8) 0.31
Race 0.2
 Non-white 48 (10%) 60 (12%)
 White 419 (87%) 395 (82%)
 Unknown 13 (3%) 25 (5%)
Year 0.88
 2012 15 (3%) 15 (3%)
 2013 152 (32%) 161 (34%)
 2014 182 (38%) 183 (38%)
 2015 131 (27%) 121 (25%)
ASA Class 0.07
 I–II 255 (53%) 284 (59%)
 III–V 225 (47%) 196 (41%)
Prior pelvic or colon surgery1 201 (42%) 201 (42%) 0.99
Indication 0.86
 Cancer 282 (59%) 282 (59%)
 Diverticulitis 64 (13%) 72 (15%)
 Inflammatory bowel disease 72 (15%) 69 (14%)
 Other indication2 62 (13%) 57 (12%)
Surgical type 0.65
 Colon Resection 359 (75%) 366 (76%)
 Rectal Resection 121 (25%) 114 (24%)
Ostomy Created 91 (19%) 91 (19%) 0.99
Insurance type 0.99
 Private insurance 249 (52%) 248 (52%)
 Non-private insurance 231 (48%) 232 (48%)
Serious adverse events 45 (9%) 34 (7%) 0.24
Length of Stay, mean (SD), day 5.8 (4.5) 5.9 (4.9) 0.92
Prolonged length of stay (≥8 days) 98 (20%) 75 (16%) 0.05
1
Prior pelvic or colon surgery includes hysterectomy, cholecystectomy, appendectomy and small bowel and colon resections in the pelvic area.
2
Other indications include arterial malformation, iatrogenic injury, rectal prolapse, stricture, or gynecologic malignancy
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